CTOs on the Move

Sherlock Biosciences

www.sherlock.bio

 
Sherlock Biosciences aims to disrupt molecular diagnostics with better, faster, affordable tests. With our unique Engineering Biology platforms, we are on the cusp of solving challenges ranging from faster pathogen detection and simpler testing for cancer to improved food safety. We envision a world where our products will enable users to make more effective decisions in any environment, whether in hospitals, industrial settings, the developing world, or at home. Our team and founders include Engineering Biology pioneers with world-leading expertise in CRISPR and Synthetic Biology, diagnostic industry veterans, and disease-area authorities. Together, they provide an unparalleled set of capabilities that ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.sherlock.bio
  • 35 Spinelli Place
    Cambridge, MA USA 02142
  • Phone: 617.702.6263

Executives

Name Title Contact Details
William Blake
Chief Technology Officer Profile

Funding

Sherlock Biosciences raised $31M on 04/23/2019
Sherlock Biosciences raised $80M on 03/08/2022

Similar Companies

Vestaron

Recent winner of the Green Chemistry award, Vestaron is leading a peptide-based revolution in crop protection. We are committed to providing growers with novel, effective chemistries that address proven targets. Our peptides overcome existing resistance issues while offering a desired safety profile for workers, beneficials and the environment. Initially, Vestaron is focused on a class of peptides that kills insect pests efficiently, but is safe for humans, birds, fish, pollinators and the environment. As part of this, the company has developed a proprietary platform for peptide optimization and fermentation-based peptide production that will allow development of a wide variety of biologic crop protection solutions. Vestaron is proud to bring you the Power of Peptides through the SPEAR® brand family - providing new technology with a unique mode of action in a biological solution equal to, and often better, than the synthetic options; creating the opportunity to incorporate a new IRAC Group 32 into rotation recommendations for resistance management.

Cleave Biosciences

Cleave Biosciences is a biopharmaceutical company pioneering the development of novel protein homeostasis inhibitors for the treatment of cancer.

Meso Scale Discovery

Meso Scale Discovery is a Gaithersburg, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Synlogic

Synlogic is a clinical-stage biotechnology company developing medicines through its proprietary approach to synthetic biology. Synlogic`s pipeline includes its lead program in phenylketonuria (PKU), which has demonstrated proof of concept with plans to start a pivotal, Phase 3 study in the second half of 2022, and additional novel drug candidates designed to treat homocystinuria (HCU) and enteric hyperoxaluria. The rapid advancement of these potential biotherapeutics, called Synthetic Biotics, has been enabled by Synlogic`s proprietary, reproducible, target-specific drug design. Synlogic uses programmable, precision genetic engineering of well-characterized probiotics to exert localized activity for therapeutic benefit, with a focus on metabolic and immunologic diseases. Synlogic is also working with Roche in a research collaboration focused on the discovery of a novel Synthetic Biotic for the treatment of inflammatory bowel disease and with Ginkgo Bioworks to include additional undisclosed preclinical assets, combining Synlogic`s approach to Synthetic Biotics with Ginkgo`s Codebase and Foundry services.

Northwest Bioanalytical

Northwest Bioanalytical is a Salt Lake City, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.